NORTHWEST BIOTHERAPEUTICS INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $6.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2026-08-14
- NORTHWEST BIOTHERAPEUTICS INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- NORTHWEST BIOTHERAPEUTICS INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2026-03-31 was $6.81M, a 209.68% increase year-over-year.
- NORTHWEST BIOTHERAPEUTICS INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2025-12-31 was $8.79M, a 22.11% decline year-over-year.
- NORTHWEST BIOTHERAPEUTICS INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2025-09-30 was $12.51M, a 301.51% increase year-over-year.
- NORTHWEST BIOTHERAPEUTICS INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2025 was $27.73M, a 39.33% increase from fiscal 2024.
- NORTHWEST BIOTHERAPEUTICS INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2024 was $19.90M, a 85.12% increase from fiscal 2023.
- NORTHWEST BIOTHERAPEUTICS INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2023 was $10.75M, a 5528.27% increase from fiscal 2022.
- NORTHWEST BIOTHERAPEUTICS INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2022 was $191.00K, a 89.30% decline from fiscal 2021.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $6.81M 10-Q · filed 2026-08-14 | $15.60M derived: sum of 3 quarters · filed 2026-08-14 | $28.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $6.81M 10-Q · filed 2026-05-15 | $15.60M derived: sum of 2 quarters · filed 2026-05-15 | $28.11M derived: sum of 3 quarters · filed 2026-05-15 | $32.34M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $8.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $21.30M derived: sum of 2 quarters · filed 2026-04-15 | $25.53M derived: sum of 3 quarters · filed 2026-04-15 | $27.73M 10-K · filed 2026-04-15 |
| 2025-09-30 | $12.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $16.74M derived: sum of 2 quarters · filed 2025-11-14 | $18.94M 10-Q · filed 2025-11-14 | $30.22M derived: sum of 4 quarters · filed 2026-04-15 |
| 2025-06-30 | $4.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $6.43M 10-Q · filed 2025-08-14 | $17.71M derived: sum of 3 quarters · filed 2026-04-15 | $20.83M derived: sum of 4 quarters · filed 2026-04-15 |
| 2025-03-31 | $2.20M 10-Q · filed 2025-05-15 | $13.48M derived: sum of 2 quarters · filed 2026-04-15 | $16.60M derived: sum of 3 quarters · filed 2026-04-15 | $16.60M derived: sum of 4 quarters · filed 2026-04-15 |
| 2024-12-31 | $11.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $14.40M derived: sum of 2 quarters · filed 2026-04-15 | $14.40M derived: sum of 3 quarters · filed 2026-04-15 | $19.90M 10-K · filed 2026-04-15 |
| 2024-09-30 | $3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.12M derived: sum of 2 quarters · filed 2024-11-12 | $8.62M 10-Q · filed 2024-11-12 | $18.86M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $5.50M 10-Q · filed 2024-08-09 | $15.74M derived: sum of 3 quarters · filed 2025-03-31 | $15.59M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $5.50M 10-Q · filed 2024-05-10 | $15.74M derived: sum of 2 quarters · filed 2025-03-31 | $15.59M derived: sum of 3 quarters · filed 2025-03-31 | $15.71M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $10.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $10.09M derived: sum of 2 quarters · filed 2025-03-31 | $10.21M derived: sum of 3 quarters · filed 2025-03-31 | $10.75M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$155.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$30.00K derived: sum of 2 quarters · filed 2023-11-09 | $508.00K 10-Q · filed 2023-11-09 | $508.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2023-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $663.00K 10-Q · filed 2023-08-09 | $663.00K derived: sum of 3 quarters · filed 2024-03-05 | $663.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2023-03-31 | $538.00K 10-Q · filed 2023-05-10 | $538.00K derived: sum of 2 quarters · filed 2024-03-05 | $538.00K derived: sum of 3 quarters · filed 2024-03-05 | $570.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $32.00K derived: sum of 3 quarters · filed 2024-03-05 | $191.00K 10-K · filed 2024-03-05 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $32.00K derived: sum of 2 quarters · filed 2022-11-09 | $191.00K 10-Q · filed 2022-11-09 | $1.46M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-06-30 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $191.00K 10-Q · filed 2022-08-09 | $1.46M derived: sum of 3 quarters · filed 2023-02-28 | $1.84M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-03-31 | $159.00K 10-Q · filed 2022-05-10 | $1.43M derived: sum of 2 quarters · filed 2023-02-28 | $1.81M derived: sum of 3 quarters · filed 2023-02-28 | $1.81M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.65M derived: sum of 2 quarters · filed 2023-02-28 | $1.65M derived: sum of 3 quarters · filed 2023-02-28 | $1.78M 10-K · filed 2023-02-28 |
| 2021-09-30 | $385.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $385.00K derived: sum of 2 quarters · filed 2021-11-15 | $516.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $131.00K 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | $131.00K 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $18.86M 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $4.11M 10-K · filed 2021-03-31 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-02 | $0.00 derived: sum of 2 quarters · filed 2019-04-02 | $4.26M 10-K · filed 2019-04-02 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $4.26M 10-Q · filed 2017-11-20 | ||
| 2017-06-30 | $4.26M 10-Q · filed 2017-08-21 | |||
| 2015-12-31 | $521.00K 10-K · filed 2017-04-17 |